IP Library › Granted Patent US 12,680,105
Granted Patent B2
US 12,680,105 · App. 17/644,931 · Granted Jul 14, 2026

Cancer antigens and methods

Inventors: George Kassiotis (London, GB); George Young (London, GB); Jan Attig (London, GB); Fabio Marino (Oxford, GB)
Assignees: Enara Bio Limited; The Francis Crick Institute Limited
C12N15/63A61K40/11A61K40/17A61K40/24A61K40/32A61K40/42A61K40/4201A61K40/4272A61K40/46A61P35/00C12N5/0638C12N5/0639A61K2239/57
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,680,105
App. No.
17/644,931
Filed
Dec 17, 2021
Granted
Jul 14, 2026
Kind
B2
Art Unit
1638
USPC
424/93.71
Abstract

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly non small cell lung cancer, especially lung squamous cell carcinoma and melanoma, especially cutaneous melanoma.

Claims (43)

1 . A composition comprising an isolated polypeptide and an immunostimulant, wherein:

(a) the isolated polypeptide consists of an amino acid sequence comprising at least 9 contiguous residues of SEQ ID NO: 1 or 2;

(b) the isolated polypeptide comprises an amino acid sequence having at least 90% identity over the entire length of SEQ ID NO: 1 or 2;

(c) the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4; or

(d) the amino acid sequence of the isolated polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4.

2 . The composition of claim 1 , wherein the immunostimulant is selected from the group consisting of aluminum salts, saponins, immunostimulatory oligonucleotides, oil-in-water emulsions, aminoalkyl glucosaminide 4-phosphates, lipopolysaccharides and derivatives thereof, TLR4 ligands, TLR7 ligands, TLR8 ligands, TLR9 ligands, IL-12, and interferons.

3 . A fusion protein comprising a first polypeptide and one or more additional polypeptides, wherein the first polypeptide:

(a) consists of an amino acid sequence comprising at least 9 contiguous residues of SEQ ID NO: 1 or 2;

(b) comprises an amino acid sequence having at least 90% identity over the entire length of SEQ ID NO: 1 or 2;

(c) comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4; or

(d) consists of an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-4.

4 . An isolated antigen-binding polypeptide which is immunospecific for a polypeptide as set forth in claim 1 , optionally wherein the antigen-binding polypeptide is an antibody or a T cell receptor, or an antigen-binding fragment of any one thereof.

5 . A vector or artificial nucleic acid sequence encoding a polypeptide, wherein the polypeptide:

(a) consists of an amino acid sequence comprising at least 9 contiguous residues of SEQ ID NO: 1 or 2;

(b) comprises an amino acid sequence having at least 90% identity over the entire length of SEQ ID NO: 1 or 2;

(c) comprises the amino acid sequence of SEQ ID NO: 1 or 2; or

(d) consists of an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-4.

6 . The artificial nucleic acid sequence of claim 5 , wherein the artificial nucleic acid is mRNA.

7 . A method of preparing a T-cell population comprising stimulating and amplifying T-cells ex vivo using a polypeptide as set forth in claim 1 .

8 . A T-cell population obtained by the method of claim 7 .

9 . A method of preparing an antigen presenting cell population, comprising introducing into antigen presenting cell ex vivo a polypeptide as set forth in claim 1 , or a nucleic acid sequence encoding the polypeptide.

10 . An antigen presenting cell population obtained by the method of claim 9 .

11 . An exosome comprising a polypeptide or a nucleic acid sequence encoding the polypeptide, wherein the polypeptide:

(a) comprises an amino acid sequence comprising at least 9 contiguous residues of SEQ ID NO: 1 or 2;

(b) comprises an amino acid sequence having at least 90% identity over the entire length of SEQ ID NO: 1 or 2;

(c) comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4; or

(d) consists of an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-4.

12 . A method of stimulating an immune response in a subject, the method comprising administering to the subject a therapeutically effective amount of a polypeptide as set forth in claim 1 , or a nucleic acid sequence encoding the polypeptide.

13 . A method of stimulating an immune response in a subject, the method comprising administering to the subject a therapeutically effective amount of the T-cell population of claim 8 .

14 . A method of stimulating an immune response in a subject, the method comprising administering to the subject a therapeutically effective amount of the antigen presenting cell population of claim 10 .

15 . A method of treating a subject suffering from a cancer expressing a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 2, or an immunogenic fragment or variant thereof, the method comprising administering to the subject a therapeutically effective amount of a polypeptide as set forth in claim 1 , or a nucleic acid sequence encoding the polypeptide.

16 . A method of treating a subject suffering from a cancer expressing a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 2, or an immunogenic fragment or variant thereof, the method comprising administering to the subject a therapeutically effective amount of the T-cell population of claim 8 .

17 . A method of treating a subject suffering from a cancer expressing a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 2, or an immunogenic fragment or variant thereof, the method comprising administering to the subject a therapeutically effective amount of the antigen presenting cell population of claim 10 .

18 . A method of diagnosing a subject as suffering from a cancer, the method comprising determining if cells of the subject comprise a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 2, or an immunogenic fragment or variant thereof, or a nucleic acid sequence expressing the polypeptide, wherein the presence of the polypeptide or nucleic acid sequence in the cells indicates that the subject has cancer.

19 . A method of making the composition of claim 1 , the method comprising combining an immunostimulant with an isolated polypeptide, wherein:

(a) the isolated polypeptide consists of an amino acid sequence comprising at least 9 contiguous residues of SEQ ID NO: 1 or 2;

(b) the isolated polypeptide comprises an amino acid sequence having at least 90% identity over the entire length of SEQ ID NO: 1 or 2;

(c) the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4; or

(d) the amino acid sequence of the isolated polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4.

20 . An isolated peptide:

(i) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and 2;

(ii) consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4; or

a salt thereof, and/or a composition thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2023
From: MARINO, FABIO
To: ENARA BIO LIMITED
Reel/Frame 062397/0973 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2023
From: KASSIOTIS, GEORGE; YOUNG, GEORGE; ATTIG, JAN
To: THE FRANCIS CRICK INSTITUTE LIMITED
Reel/Frame 062397/0989 →
Priority Claims (1)
EP 19184742 · Jul 5, 2019 · regional
Continuity (2)
Continuation PCTGB2020051594 · Jul 3, 2020
Related Publication 20220211760A1 · Jul 7, 2022
References Cited (154)
US 6566325B2 · Moore et al. · 2003 [cited by applicant]
US 7504490B1 · Weinstock et al. · 2009 [cited by applicant]
US 7745391B2 · Mintz et al. · 2010 [cited by applicant]
US 11666644B2 · Lisziewicz et al. · 2023 [cited by applicant]
US 12263216B2 · Kassiotis et al. · 2025 [cited by applicant]
US 20020082206A1 · Leach et al. · 2002 [cited by applicant]
US 20070072175A1 · Cooper et al. · 2007 [cited by applicant]
US 20070083334A1 · Mintz et al. · 2007 [cited by applicant]
US 20100136518A1 · Humer et al. · 2010 [cited by applicant]
US 20100285509A1 · Mayer et al. · 2010 [cited by applicant]
US 20110183924A1 · Mintz et al. · 2011 [cited by applicant]
US 20110217326A1 · Kudo et al. · 2011 [cited by applicant]
US 20140099324A1 · Wang-Johanning · 2014 [cited by applicant]
US 20150119265A1 · Perot et al. · 2015 [cited by applicant]
US 20160160295A1 · Chinnaiyan et al. · 2016 [cited by applicant]
US 20180015975A1 · Fritsch et al. · 2018 [cited by examiner]
US 20190322721A1 · Sonntag et al. · 2019 [cited by applicant]
US 20190351040A1 · Valiente et al. · 2019 [cited by applicant]
US 20210353729A1 · Kassiotis et al. · 2021 [cited by applicant]
US 20220211760A1 · Kassitois et al. · 2022 [cited by applicant]
US 20220213159A1 · Kassiotis et al. · 2022 [cited by applicant]
US 20220218807A1 · Kassiotis et al. · 2022 [cited by applicant]
US 20220220175A1 · Kassiotis et al. · 2022 [cited by applicant]
US 20230167163A1 · Kassiotis et al. · 2023 [cited by applicant]
US 20230302109A1 · Kassiotis et al. · 2023 [cited by applicant]
US 20240156932A1 · Davies et al. · 2024 [cited by applicant]
EP 1580263A1 · 2005 [cited by applicant]
EP 2878678A1 · 2015 [cited by applicant]
JP 2003304877A · 2003 [cited by applicant]
TW 1658050 · 2019 [cited by examiner]
WO WO2000006598A1 · 2000 [cited by applicant]
WO 2001064835A2 · 2001 [cited by applicant]
WO 200175067A2 · 2001 [cited by applicant]
WO WO2001077330A2 · 2001 [cited by applicant]
WO 2004038003A2 · 2004 [cited by applicant]
WO WO2005099750A1 · 2005 [cited by applicant]
WO 2006105642A1 · 2006 [cited by applicant]
WO WO2006103562A2 · 2006 [cited by applicant]
WO WO2006119527A2 · 2006 [cited by applicant]
WO 2007073478A2 · 2007 [cited by applicant]
WO WO2007109583A2 · 2007 [cited by applicant]
WO WO2007137279A2 · 2007 [cited by applicant]
WO WO2008016356A2 · 2008 [cited by applicant]
WO 2008118258A2 · 2008 [cited by applicant]
WO WO2009026116A2 · 2009 [cited by applicant]
WO WO2009039244A2 · 2009 [cited by applicant]
WO 2013033333A1 · 2013 [cited by applicant]
WO 2013040142A2 · 2013 [cited by applicant]
WO 2013041142A1 · 2013 [cited by applicant]
WO 2014004385A2 · 2014 [cited by applicant]
WO 2017097602A1 · 2017 [cited by applicant]
WO WO2017097699A1 · 2017 [cited by applicant]
WO 2019133934A2 · 2019 [cited by applicant]
WO WO2020079448A1 · 2020 [cited by applicant]
WO 2020257922A1 · 2020 [cited by applicant]
WO WO2020260897A1 · 2020 [cited by applicant]
WO WO2020260898A2 · 2020 [cited by applicant]
WO 2021005338A2 · 2021 [cited by applicant]
WO 2021005339A1 · 2021 [cited by applicant]
WO 2021209775A1 · 2021 [cited by applicant]
WO 2021212123A1 · 2021 [cited by applicant]
WO 2022229647A1 · 2022 [cited by applicant]
WO 2023230573A2 · 2023 [cited by applicant]
WO 2025133007A1 · 2025 [cited by applicant]
Nagata et al., “Synthesis and biological activity of artificial mRNA prepared with novel phosphorylating agents” Nucleic Acid Res ( Year: 2010). [cited by examiner]
Nagata et al., “Synthesis and biological activity of artificial mRNA prepared with novel phosphyerlating agents” Nucleic Acid Res. ( Year: 2010). [cited by examiner]
Luan et al., “Engineering exosomes as refined biological nanoplatforms for drug delivery” (Year: 2017). [cited by examiner]
Pandiani, Charlotte, et al. “Focus on cutaneous and uveal melanoma specificities.” Genes & development 31.8 (2017): 724-743. [cited by applicant]
“Acetyltransferase,” EBI Accession No. UNIPROT: D6AHI5. [cited by applicant]
Attermann et al., “Human endogenous retroviruses and their implication for immunotherapeutics of cancer,” Ann Oncol. Nov. 1, 2018;29(11):2183-2191. [cited by applicant]
Attig et al., “Physiological and Pathological Transcriptional Activation of Endogenous Retroelements Assessed by RNA-Sequencing of B Lymphocytes,” Front Microbiol. Dec. 12, 2017;8:2489. [cited by applicant]
Attig et al., “LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly,” Genome Res. Oct. 2019;29(10):1578-1590(supplemental materials). [cited by applicant]
Bannert et al., “HERVs new role in cancer: from accused perpetrators to cheerful protectors,” Front Microbiol. Feb. 13, 2018;9:178. [cited by applicant]
Cegolon et al., “Human endogenous retroviruses and cancer prevention: evidence and prospects,” BMC Cancer. Jan. 3, 2013;13:4. [cited by applicant]
Escudier et al., “Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial,” J Transl Med. Mar. 2, 2005;3:10. [cited by applicant]
Ferrucci et al., “Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment,” Curr Top Med Chem. 2012;12(1):11-31. [cited by applicant]
“ [cited by applicant]
“ [cited by applicant]
Jayson et al., “Ovarian cancer,” Lancet. Oct. 11, 2014;384(9951):1376-88. [cited by applicant]
“Macaca fuscata fuscata DNA, clone: MSB2-228H05_R, genomic survey sequence,” EBI Accession No. AG759599. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/GB2021/050940, dated Aug. 3, 2021. [cited by applicant]
PCT International Search Report and Written Opinion from PCT/US2021/028029, dated Aug. 9, 2021. [cited by applicant]
Schuster et al., “The immunopeptidomic landscape of ovarian carcinomas,” Proc Natl Acad Sci U S A. Nov. 14, 2017;114(46):E9942-E9951. [cited by applicant]
“UI-H-DPO-avc-g-14-0-UI.s1 NCI_CGAP_Fs1 [cited by applicant]
UniParc—UPI00060150B7. [cited by applicant]
Yin et al., “Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity,” Inflammation. Feb. 2013;36(1):232-40. [cited by applicant]
Attig et al., Supplemental Material—“LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly,” Genome Res. Oct. 2019;29(10): (160 pages). [cited by applicant]
Acha-Orbea and MacDonald, “Superantigens of mouse mammary tumor virus,” Annu Rev Immunol. 1995;13:459-86. [cited by applicant]
Andersson et al., “Expression of human endogenous retrovirus ERV3 (HERV-R) mRNA in normal and neoplastic tissues,” Int J Oncol. Feb. 1998;12(2):309-13. [cited by applicant]
Attig et al., “LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly,” Genome Res. Oct. 2019;29(10):1578-1590. [cited by applicant]
Aung et al., “Expression of NY-ESO-1 in primary and metastatic melanoma,” Hum Pathol. Feb. 2014;45(2):259-67. [cited by applicant]
Babaian and Mager, “Endogenous retroviral promoter exaptation in human cancer,” Mob DNA. Dec. 1, 2016;7:24. [cited by applicant]
Bassani-Sternberg et al., “Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry,” Nat Commun. Nov. 21, 2016;7:13404. [cited by applicant]
Bulik-Sullivan et al., “Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification,” Nat Biotechnol. Jan. 2019;37(1):55-63. [cited by applicant]
Cherkasova et al., “Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors,” Front Oncol. Sep. 17, 2013;3:243. [cited by applicant]
Gigoux and Wolchok, “Refusing to TAP out: 16 new human TEIPPs identified,” J Exp Med. Sep. 3, 2018;215(9):2233-2234. [cited by applicant]
Hoyos and Abdel-Wahab, “Cancer-specific splicing changes and the potential for splicing-derived neoantigens,” Cancer Cell. Aug. 13, 2018;34(2):181-183. [cited by applicant]
Humer et al., “Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses,” Cancer Res. Feb. 1, 2006;66(3):1658-63. [cited by applicant]
Hurst and Magiorkinis, “Activation of the innate immune response by endogenous retroviruses,” J Gen Virol. Jun. 2015;96(Pt 6):1207-1218. [cited by applicant]
Kahles et al., “Comprehensive analysis of alternative splicing across tumors from 8,705 patients,” Cancer Cell. Aug. 13, 2018;34(2):211-224.e6. [cited by applicant]
Kassiotis and Stoye, “Immune responses to endogenous retroelements: taking the bad with the good,” Nat Rev Immunol. Apr. 2016;16(4):207-19. [cited by applicant]
Katoh and Kurata, “Association of endogenous retroviruses and long terminal repeats with human disorders,” Front Oncol. Sep. 11, 2013;3:234. [cited by applicant]
Kershaw et al., “Immunization against endogenous retroviral tumor-associated antigens,” Cancer Res. Nov. 1, 2001;61(21):7920-4. [cited by applicant]
Laumont et al., “Noncoding regions are the main source of targetable tumor-specific antigens,” Sci Transl Med. Dec. 5, 2018;10(470):eaau5516. [cited by applicant]
Lauss et al., “Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma,” Nat Commun. 2017;8:1738. [cited by applicant]
Lock et al., “Distinct isoform of FABP7 revealed by screening for retroelement-activated genes in diffuse large B-cell lymphoma,” Proc Natl Acad Sci U S A. Aug. 26, 2014;111(34):E3534-43. [cited by applicant]
Mangeney et al., “The full-length envelope of an HERV-H human endogenous retrovirus has immunosuppressive properties,” J Gen Virol. Oct. 2001;82(Pt 10):2515-2518. [cited by applicant]
Marijt et al., “Identification of non-mutated neoantigens presented by TAP-deficient tumors,” J Exp Med. Sep. 3, 2018;215(9):2325-2337. [cited by applicant]
Ribas and Wolchok, “Cancer immunotherapy using checkpoint blockade,” Science. Mar. 23, 2018;359(6382):1350-1355. [cited by applicant]
Ruprecht et al., “Endogenous retroviruses,” Cell Mol Life Sci. Nov. 2008;65(21):3366-82. [cited by applicant]
Sacha et al., “Vaccination with cancer-and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic,” J Immunol. Aug. 1, 2012;189(3):1467-79. [cited by applicant]
Schiavetti et al., “A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes,” Cancer Res. Oct. 1, 2002;62(19):5510-6. [cited by applicant]
DNA fragments of a human Tox gene, 47247, EBI Accession No. GSN: ARC03196 (1 page). [cited by applicant]
Human derived non-coding RNA MEAT62.1, SEQ:1895, EBI Accession No. GSN: BCQ58603 (1 page). [cited by applicant]
Sequence Aspergillus fumigatus ORF amino acid sequence SEQ ID No. 31732, EBI Accession No. GSP: AWP60286 (1 page). [cited by applicant]
Sequence Human ORF553, Ebi Accession No. GSP: ABP64183 (1 page). [cited by applicant]
Sequence Human derived non-coding RNA CAT2186.2 SEQ: 1274, EBI accession No. GSN: BCQ57982 (2 pages). [cited by applicant]
Sequence SubName: Full = Acetyltransferase, EBI Accession No. UNIPROT: D6AHI5 (1 page). [cited by applicant]
Slansky et al., “Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex,” Immunity. Oct. 2000;13(4):529-38. [cited by applicant]
Smart et al., “Intron retention is a source of neoepitopes in cancer” Nat Biotechnol. Dec. 2018;36(11):1056-1058. [cited by applicant]
Ternette et al., “Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens,” Proteomics. Jun. 2018;18(12):e1700465. [cited by applicant]
Wang-Johanning et al., “Detecting the expression of human endogenous retrovirus E envelope transcripts in human prostate adenocarcinoma,” Cancer. Jul. 1, 2003;98(1):187-97. [cited by applicant]
Wold and Toth, “Adenovirus vectors for gene therapy, vaccination and cancer gene therapy,” Curr Gene Ther. Dec. 2013;13(6):421-33. [cited by applicant]
Yossef et al., “Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy,” JCI Insight. Oct. 4, 2018;3(19):e122467. [cited by applicant]
“Pricing and Ordering—Commercial”, Proteomics International, Retrieved from: https://www.proteomics.com.au/analytical-services/pricing-and-ordering/, Apr. 1, 2014, 7 pages. [cited by applicant]
Abbott et al., “Abstract 312: Identification of novel non-small cell lung cancer (NSCLC) Dark Antigens (TM), with expression in multiple tumor types, as promising targets for immunotherapies”, Retrieved from: https://ji… [cited by applicant]
Abbott et al., “Abstract 343: Identification of Tumor-Reactive T Cells Targeting Melanoma Dark Antigens(TM) Validates This Novel Class of Targets For Development of Immunotherapies”, Retrieved from: https://jitc.bmj.com… [cited by applicant]
Abbott et al., “Identification of novel non-small cell lung cancer (NSCLC) Dark Antigens (TM), with expression in multiple tumor types, as promising targets for immunotherapies”, Retrieved from: https://enarabio.ams3.cd… [cited by applicant]
Finney et al., “Germinal center responses to complex antigens”, Immunological Reviews, 2018, 284(1):42-50. [cited by applicant]
Lin et al., “Melanoma-associated antigens in esophageal adenocarcinoma: Identification of novel MAGE-A10 splice variants”, Journal of the American College of Surgeons, 2004, 199(3):S32. [cited by applicant]
Matsuzaki et al., “Systematic Identification of Human Melanoma Antigens Using Serial Analysis of Gene Expression (SAGE)”, Journal of Immunotherapy, Jan./Feb. 2005, 28(1):10-19. [cited by applicant]
Nelde et al., “The Peptide Vaccine of the Future”, Molecular Cell Proteomics, 2021, 20:100022, pp. 1-11. [cited by applicant]
Paul et al., “HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity”, The Journal of Immunology, Dec. 15, 2013, 191(12):5831-5839. [cited by applicant]
Sela-Culang et al., “The structural basis of antibody-antigen recognition”, Frontiers in Immunology, Oct. 2013, 4 (Article 302), pp. 1-13. [cited by applicant]
Zhao et al., “Proteogenomics uncovers a vast repertoire of shared tumor-specific antigens in ovarian cancer”, Cancer Immunology Research, Apr. 2020, 8(4):544-555. [cited by applicant]
Zitvogel et al., “Eradication of established murine tumours using a novel cell-free vaccine: dendritic cell-derived exosomes”, Nature Medicine, May 1998, 4(5):594-600. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/GB2019/052980, mailed on Jan. 29, 2021, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/GB2020/051557, mailed on Dec. 10, 2021, 10 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/GB2020/051558, mailed on Jan. 6, 2022, 15 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/GB2020/051592, mailed on Oct. 19, 2021, 8 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/GB2020/051594, mailed on Jan. 20, 2022, 10 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/GB2021/050940, completed on Jun. 24, 2022, 11 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/GB2022/051086, mailed on Jul. 19, 2023, 8 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2021/028029, mailed on Jul. 13, 2022, 15 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/EP2024/087738, mailed on Jun. 3, 2025, 19 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/GB2019/052980, mailed on Apr. 20, 2020, 21 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/GB2020/051557, mailed on Sep. 22, 2020, 11 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/GB2020/051558, mailed on Dec. 23, 2020, 19 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/GB2020/051592, mailed on Jan. 18, 2021, 22 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/GB2020/051594, mailed on Sep. 16, 2020, 13 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/GB2022/051086, mailed on Aug. 19, 2022, 19 pages. [cited by applicant]
U.S. Appl. No. 62/866,089. [cited by applicant]
U.S. Appl. No. 19/062,913, Kassiotis et al., filed Feb. 25, 2025. [cited by applicant]
U.S. Appl. No. 19/249,526, Kundu et al., filed Jun. 25, 2025. [cited by applicant]